Brainsway has developed Deep TMS (Transcranial Magnetic Stimluation) for non-invasive treatment of a range of neurological and psychiatric disorders. The company is joining drug developers BiolineRX Ltd. (TASE:BLRX) and Biocancell Therapeutics Ltd. (TASE:BICL) in plans to hold offerings on Nasdaq. "Globes" was the first to report that Biocancell is seeking to raise $10 million on Wall Street.
Brainsway, run by CEO Uzi Sofer, currently trades at a market cap of NIS 341 million. It had NIS 23 million in cash at the end of March. The company did not disclose how much it wants to raise on Nasdaq, or at what company value. It is also not known whether it will aim for a premium on its market cap on the TASE, but D Medical's experience last week demonstrated that obtaining such a premium is not easy.
Brainsway's share price rose 5.6% by mid-afternoon on the TASE to NIS 8.52.
You comment was recieved and soon will be published.
Thank you for posting your comment, which will be reviewed for publication.
Load more comments